Influence of methylenetetrahydrofolate reductase gene polymorphisms on the outcome of pediatric patients with non-Hodgkin lymphoma treated with high-dose methotrexate

References

• De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine based therapy. Eur J Cancer 2009;60:1–19.
   Google Scholar
• Gemmati D, Ongaro A, Tognazzo S, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. Haematologica 2007;92:478–485.
   PubMed Web of Science ®Google Scholar
• Kim HN, Kim YK, Lee IK, et al. Association between polymorphisms of folate-metabolizing enzymes and haematological malignancies. Leuk Res 2009;33:82–87.
   PubMed Web of Science ®Google Scholar
• Bottiger AK, Hurtig-Wennlof A, Sjostrom M, et al. Association of total plasma homocysteine with methylenetetrahydrofolate reductase genotypes 677C> T, 1298A> C, and 1793G> A and the corresponding haplotypes in Swedish children and adolescents. Int J Mol Med 2007;19:659–665.
   PubMed Web of Science ®Google Scholar
• Kremer JM. Methotrexate pharmacogenomics. Ann Rheum Dis 2006;65:1121–1123.
   PubMed Web of Science ®Google Scholar
• D’Angelo V, Ramaglia M, Iannotta A, et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol 2011;68:1339–1346.
   PubMed Web of Science ®Google Scholar
• Yang L, Hu X, Xu LH. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-indued toxicity in acute lymphoblastic leukemia: a meta-analysis. Tumor Biol 2012;33:1445–1454.
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster group. J Clin Oncol 1995;13:359–372.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005;105:948–958.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835–3849.
   PubMed Web of Science ®Google Scholar
• WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48. Geneva: World Health Organization; 1979.
   Google Scholar
• Boyle E, Steinbuchn M, Tekautz T, et al. Accuracy of DNA amplification from archival haematological slides for use in genetic biomarker studies. Cancer Epidemiol 1998;7:1127–1131.
   PubMed Web of Science ®Google Scholar
• Weisberg I, Tran P, Christensen B, et al. A second genetic polymorphism in methylentetrahydofolaten reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169–172.
   PubMed Web of Science ®Google Scholar
• Murphy SB. Classification, staging and end results of treatment in childhood non Hodgkin's lymphoma: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332–339.
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004;5:819–834.
   PubMed Web of Science ®Google Scholar
• El-Khodary NM, EL-Haggar SM, Eid MA, et al. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol 2012;29:2053–2062.
   PubMed Web of Science ®Google Scholar
• Costea I, Moghrabi A, Laverdiere C, et al. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 2006;91:1113–1116.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Mori T, Samejima H, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006;28:64–68.
   PubMed Web of Science ®Google Scholar
• Horinouchi M, Yagi M, Imanishi H, et al. Association of genetic polymorphismis with hepatotoxicity in patients with chilhood acute lymphoblastic leukemia or lymphoma. Pediatr Hematol Oncol 2010;27:344–354.
   PubMed Web of Science ®Google Scholar
• Erčulj N, Kotnik BF, Debeljak M, et al. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2012;53:1096–1104
   PubMed Web of Science ®Google Scholar
• Ongaro A, De Mattei M, Della Porta MG, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 2009;94:1391–1398.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009;146:489–503.
   PubMed Web of Science ®Google Scholar
• Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab 2009;10:547–566.
   PubMed Web of Science ®Google Scholar
• Kim YI. Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol 2009;5:523–542.
   PubMed Web of Science ®Google Scholar
• Kantar M, Kosova B, Centingul N, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50:912–917.
   PubMed Web of Science ®Google Scholar
• Seidemann K, Book M, Zimmermann M, et al. MTHFR 677 (C→T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Ann Hematol 2006;85:291–300.
   PubMed Web of Science ®Google Scholar
• Cunningham L, Aplenc R. Role of the folate-pathway and the thymidylate synthase genes in pediatric acute lymphoblastic leukemia treatment response. In: Innocenti F, editor. Genomics and pharmacogenomics in anticancer drug development and clinical response. Totowa, NJ: Humana Press 2008. pp 299–312.
   Google Scholar
• Chiusolo P, Giammarco S, Bellesi S, et al. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with haematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemother Pharmacol 2012; 69:691–696.
   PubMed Web of Science ®Google Scholar